22nd May 2018, Stockholm, Oslo. Hadean Ventures today announces an investment in AttgeNO AB, a Swedish pharmaceutical company developing treatments for acute life-threatening conditions. The lead candidate Supernitro (PDNO) is targeting acute pulmonary hypertension which may occur in intensive care patients and can lead to fatal outcome. A syndicate of new and current investors are investing SEK 30m to finance clinical Phase I studies.
Acute pulmonary hypertension (PH) is a severe condition typically seen in intensive care patients, in which the blood vessels of the lungs contract and make it difficult for the heart to pump blood through the pulmonary circuit. This may result in pronounced heart failure and sudden death. AttgeNO’s Supernitro is based on nitrogen oxide (NO), a naturally occurring, vasodilating substance. Supernitro selectively reduces blood pressure in the lungs and thereby has the potential to treat the underlying cause of the condition.
– “Our molecule passes with the blood to the lungs and lowers the pressure in the pulmonary circulation through targeted dilation of the pulmonary blood vessels. This avoids the side effects of lowering the systemic blood pressure, which also may be fatal to the critically ill patient”, says Per Agvald, CEO of AttgeNO AB.
– “There is a lack of adequate treatment options for acute PH. Supernitro is leveraging the well-known effects of NO and has shown strong pre-clinical data. We are very excited to work with the team on its mission to tackle this serious problem”, says Ingrid Teigland Akay, Managing Partner at Hadean Ventures.
About AttgeNO. AttgeNO AB is a Swedish drug development company founded by world-leading researchers at the Karolinska Institute in Stockholm. The team has found a method of producing completely new nitrogen oxide (NO) containing substances with unique properties. The patented drug candidates have been studied in various animal models of diseases for circulatory system disorders.
About Hadean Ventures. Hadean Ventures is a European life science fund manager that invests in life science companies across Europe with a particular focus on the Nordic region. Hadean Ventures is managing funds backed by leading private and institutional investors including Argentum and Saminvest. Hadean Ventures has offices in Oslo and Stockholm and collaborates with world class academic institutions and start-up hubs across the region.
Ingrid Teigland Akay, Hadean Ventures, Managing Partner email@example.com